Biomerica (BMRA) Fundamental Analysis: Revenue, Earnings & Valuation

0.44 / 10

Underperform

Fundamental analysis rates Biomerica as Underperform with a 0.4/10 score. Asset‑MV and Profit‑MV are modestly bullish, while Revenue‑MV, Cash‑MV, ROA and profit margins are weak, indicating a challenging financial outlook.

Analysis Checks(3/10)

Revenue-MV

Value-0.97

Score0/3

Weight38.48%

1M Return-4.18%

ROA (%)

Value-65.44

Score0/3

Weight42.51%

1M Return-6.58%

Net cash flow from operating activities / Operating revenue (%)

Value-72.32

Score1/3

Weight12.65%

1M Return-1.35%

Profit-MV

Value0.66

Score2/3

Weight-36.34%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-65.44

Score0/3

Weight42.51%

1M Return-6.58%

EBIT / Total operating revenue (%)

Value-96.72

Score1/3

Weight7.15%

1M Return-0.83%

Asset-MV

Value-0.55

Score3/3

Weight-55.21%

1M Return4.62%

Net profit / Total operating revenue (%)

Value-93.64

Score1/3

Weight8.17%

1M Return-0.84%

Cash-MV

Value0.02

Score1/3

Weight34.45%

1M Return-4.16%

Net profit / Total profit (%)

Value100.02

Score2/3

Weight5.63%

1M Return-0.54%

Is BMRA undervalued or overvalued?

BMRA scores 0.44/10 on fundamentals and holds a Premium valuation at present. Backed by its -30.87% ROE, -90.31% net margin, -1.64 P/E ratio, 1.49 P/B ratio, and -48.52% earnings growth, these metrics solidify its Underperform investment rating.